β
Outcome MeasureQuality of Life

QLES-Q-SF

Quality of Life Enjoyment and Satisfaction Questionnaire – Short Form

6 Papers in Blossom

Outcome Data Across Studies

Reported results for QLES-Q-SF across 5 studies with quantitative data.

Outcome data across 9 study arm–timepoint observations
SD
Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial
2023Exploratory
Psilocybin(experimental)051———
Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial
2023Exploratory
Placebo(inactive)053———
Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: A phase 2b randomized controlled trial
2025Exploratory
Psilocybin 25 mg(experimental)4917—Δ——
Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: A phase 2b randomized controlled trial
2025Exploratory
Niacin 100 mg (active placebo)(active)4918—Δ——
Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial
2025Secondary
Psilocybin(experimental)211210.9Δ——
Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial
2025Secondary
Psilocybin(experimental)841113.0Δ——
GH001 vs Placebo in Patients With Treatment-Resistant Depression A Randomized Clinical Trial
2026Secondary
GH001 (DB)(experimental)840—Δ——
GH001 vs Placebo in Patients With Treatment-Resistant Depression A Randomized Clinical Trial
2026Secondary
Placebo (DB)(inactive)841—Δ——
LSD microdosing in major depressive disorder: results from an open-label trial
2026Secondary
LSD microdose(experimental)5619—Δ——

Papers Using QLES-Q-SF

Open Accessindividual

GH001 vs Placebo in Patients With Treatment-Resistant Depression A Randomized Clinical Trial

This randomised, double-blind, placebo-controlled phase 2b trial (n=81) found that a single-day inhaled synthetic mebufotenin treatment (GH001; 5-MeO-DMT) reduced depression symptoms more than placebo in adults with treatment-resistant depression, with remission in over half of those treated. No severe or serious adverse events were reported during the placebo-controlled period.

Published
Journal
JAMA Psychiatry
Authors
Cubała, W. J., Bajbouj, M., Bauer, M., Baune, B. T., Cardoner, N., Devlin, F., Doolin, K., Dueñas Herrero, R. M., Elices, M., Feeney, A., Gałuszko-Węgielnik, M., Jakuszkowiak-Wojten, K., Janů, L., Kelly, J. R., Ledden, K., Maclsaac, R., Madero, S., McInerney, S. J., Montejo, A. L., Nawka, A., Páleníček, T., Pérez Solà, V., Ramaekers, J. G., Reif, A., Ritter, P., Ryan, F., Svendsen, C. B., Sweeney, C., Terwey, T. H., Trivedi, M. H., Valcheva, V., Vieta, E., Thase, M. E.
Open Accessindividual

LSD microdosing in major depressive disorder: results from an open-label trial

This open-label Phase IIa trial (n=19, 15 male) found that an 8-week regimen of microdosed LSD (8μg initially, then 6-20μg twice weekly) for major depressive disorder was well-tolerated with no serious adverse events or cardiac valvulopathy, achieved 59.5% reduction in MADRS scores sustained for six months, and had only one withdrawal due to anxiety.

Published
Journal
Neuropharmacology
Authors
Daldegan-Bueno, D., Donegan, C. J., Sumner, R. L., Forsyth, A., Evans, W. J., Alshakhouri, M., Reynolds, L. M, Roop, P., Ponton, R., Smith, T., Hoeh, N. R., Allen, N., Sundram, F., Menkes, D. B., Muthukumaraswamy, S.
Open Accessindividual

Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: A phase 2b randomized controlled trial

This double-blind placebo-controlled trial (n=35) found that psilocybin-assisted psychotherapy (25mg) significantly reduced depression and anxiety symptoms in adults with life-threatening illnesses compared to an active placebo (100mg niacin), with benefits sustained at 26 weeks and improvements in spiritual well-being, quality of life, demoralisation, and death anxiety.

Published
Journal
General Hospital Psychiatry
Authors
Ross, M. L., Iyer, R., Williams, M. L., Boughey, M., O'callaghan, C., Hiscock, R., Dwyer, J.
Open Accessindividual

Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial

This open-label trial (n=12) conducted at Sheppard Pratt Hospital finds that psilocybin (25mg) significantly decreases depressive symptoms in patients with severe treatment-resistant depression (TRD) at 3 weeks (MADRS −15.8) and 12 weeks (MADRS −17.2) post-treatment. Exploratory analyses suggest the Oceanic Boundlessness dimension correlates with antidepressant responses, while patients with comorbid PTSD show reduced antidepressant effects.

Published
Journal
American Journal of Psychiatry
Authors
Aaronson, S. T., Van Der Vaart, A., Miller, T., Lapratt, J., Swartz, K., Shoultz, A., Lauterbach, M., Suppes, T., Sackeim, H. A.
Paywallindividual

Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial

In a randomised, double‑blind phase 2 trial of 104 adults with moderate-to-severe major depressive disorder, a single 25 mg dose of psilocybin with psychological support produced significantly greater and sustained reductions in depressive symptoms (MADRS mean difference −12.3 at day 43) and functional disability versus niacin placebo. No serious treatment‑emergent adverse events were reported, although psilocybin was associated with higher overall and severe adverse event rates.

Published
Journal
JAMA
Authors
Raison, C. L., Sanacora, G., Woolley, J. D., Ross, S., Griffiths, R. R.
Open Accessindividual

Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial

This double-blind placebo-controlled study (n=56) found that one psilocybin-assisted therapy (16mg/70kg, 2 prep + 3 integration meetings) session significantly reduced depressive symptoms (MADRS & BDI) in those suffering from a major depressive disorder (MDD, n=26). Fourteen days after the intervention, 54% of those in the psilocybin group met remission criteria (<10 on MADRS).

Published
Journal
EClinicalMedicine
Authors
Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., Vollenweider, F. X., van Rotz, R.

Quick Facts

Full Name
Quality of Life Enjoyment and Satisfaction Questionnaire – Short Form
Domain
Quality of Life
Papers Indexed
6
Score Range
14–70
Interpretation
Higher = better
All Measures